Durvalumab combined with CSF-1R inhibitor SNDX-6352 improved overall survival (OS) in previously treated intrahepatic cholangiocarcinoma patients without causing any serious adverse effects, indicating the great potential of the CSF-1R inhibitor immunotherapy [130]. The gene discussed is CSF1R; the disease is intrahepatic cholangiocarcinoma.